DDrare: Database of Drug Development for Rare Diseases

Searched query = "Progressive supranuclear palsy", "PSP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 18F-AV-1451; 18F-FDG; 18F-RO6958948; 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione; AB1010; ABBV-8E12; AL; AL-108; ASK Nr. 21972; AZP2006 oral solution; Alpha-lipoic acid and L-acetyl carnitine; Anti-Parkinson medication; Antisense oligonucleotide; Azilect; BIIB092; BMS-986168; BMS986168; BOTULINUM TOXIN TYPE A; Balance; Bepranemab; Botulinum toxin type A; Carnitine; CoQ10; Coenzym Q10 Nanodispersion; Coenzym Q10, Ubiquinon, Ubichinon; Coenzyme Q10; Creatine; DaTSCAN™ Ioflupane (123I) Injection; DaTscan; Datscan; Davunetide; Davunetide (AL-108, NAP); Device: Deep Brain Stimulation; Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau; Diagnostic Test: Flutemetamol F18 Injection; Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau; Diagnostic Test: [18F]-RO6958948; Donepezil; Droxidopa; Emeramide; Exelon 1,5 mg Hartkapseln; Exelon 3,0 mg Hartkapseln; Exelon 6,0 mg Hartkapseln; F-18; F-18 AV 1451; Flortaucipir; Flortaucipir F18; Flutemetamol; Flutemetamol F18; Fresh Frozen Plasma; GDNF & Synchro Med Infusion System; Gold; Hydrogen; Leucine; Lipoic acid; Lithium; MASITINIB MESYLATE; Masitinib; Masitinib 100mg; Masitinib 200mg; Masitinib mesylate; N1,N3-BIS(2-MERCAPTOETHYL) ISOPHTHALAMIDE; NBMI; NP031112; NP031112 600mg; NP031112 800mg; NT 101; Niacinamide; Nitrogen; Other: 13C6 Leucine; Placebo; Procedure: Brain PET scan; Pyruvate, creatine, niacinamide; RASAGILINE MESILATE; RIVASTIGMINE; Raclopride; Radiopharmaceuticals; Rasagilin; Rasagiline; Riluzole; Rivastigmine; Salsalate; Single dose C2N-8E12; Stem cell therapy; Sugar pill; Suvorexant; TPI 287 2 mg/m2; TPI-287 20 mg/m2; TPI-287 6.3 mg/m2; Tideglusib; Tolfenamic Acid; Tolfenamic acid; Trihexyphenidyl; UCB0107 (bepranemab); Ubidecarenon; Valproic acid; Vizamyl; Vizamyl (flutemetamol(F-18)); Water; Xeomin; Zolpidem; [18F]Florbetapir; [18F]MNI-815 (MNI-815); [18F]MNI-952; [18F]MNI-958; [18F]T807 ([18F]MNI-777); [F18]-FDDNP

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2016-002554-21-GR (EUCTR)	09/03/2018	02/01/2018	Study of BIIB092 in Participants With Progressive Supranuclear Palsy	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy	Progressive supranuclear palsy MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Biogen Idec Research Limited	NULL	Not Recruiting			Female: yes Male: yes	396	Phase 2	United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France;Canada;Australia;Germany;Japan;Korea, Republic of
2	EUCTR2016-002554-21-DE (EUCTR)	18/08/2017	19/04/2017	A study of BIIB092 in participants with Progressive Supranuclear Palsy	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB0092 in Participants with Progressive Supranuclear Palsy	Progressive supranuclear palsy MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: BIIB092 INN or Proposed INN: BIIB092 Other descriptive name: BIIB092	Biogen Idec Research Limited	NULL	Not Recruiting			Female: yes Male: yes	459	Phase 2	United States;Greece;Spain;Austria;Russian Federation;Italy;United Kingdom;France;Canada;Australia;Germany;Japan;Korea, Republic of
3	EUCTR2016-002554-21-GB (EUCTR)	21/07/2017	10/04/2017	Study of BIIB092 in Participants With Progressive Supranuclear Palsy	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy	Progressive supranuclear palsy MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: BIIB092 INN or Proposed INN: BIIB092 Other descriptive name: BIIB092	Biogen Idec Research Limited	NULL	Not Recruiting			Female: yes Male: yes	459	Phase 2	Canada;Australia;Germany;Japan;Korea, Republic of;United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France
4	EUCTR2016-002554-21-AT (EUCTR)	30/06/2017	20/04/2017	Study of BIIB092 in Participants With Progressive Supranuclear Palsy	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy	Progressive supranuclear palsy MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: BIIB092 INN or Proposed INN: BIIB092 Other descriptive name: BIIB092	Biogen Idec Research Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	459	Phase 2	United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France;Canada;Australia;Germany;Japan;Korea, Republic of
5	NCT03068468 (ClinicalTrials.gov)	June 1, 2017	27/2/2017	Study of BIIB092 in Participants With Progressive Supranuclear Palsy	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy	Supranuclear Palsy, Progressive	Drug: BIIB092;Drug: Placebo	Biogen	NULL	Terminated	41 Years	86 Years	All	490	Phase 2	United States;Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	NCT02658916 (ClinicalTrials.gov)	February 22, 2016	13/1/2016	Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003	A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered BIIB092 in Patients With Progressive Supranuclear Palsy Who Participated in Study CN002003	Supranuclear Palsy, Progressive	Drug: BIIB092	Biogen	NULL	Terminated	41 Years	86 Years	All	47	Phase 1	United States
7	NCT02460094 (ClinicalTrials.gov)	October 2, 2015	20/5/2015	Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy	A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear Palsy	Progressive Supranuclear Palsy	Drug: BIIB092;Drug: Placebo	Biogen	NULL	Completed	41 Years	86 Years	All	48	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2016-002554-21-GR
(EUCTR)

09/03/2018

02/01/2018

Study of BIIB092 in Participants With Progressive Supranuclear Palsy

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy

Progressive supranuclear palsy
MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Biogen Idec Research Limited

NULL

Not Recruiting

Female: yes
Male: yes

396

Phase 2

United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France;Canada;Australia;Germany;Japan;Korea, Republic of

EUCTR2016-002554-21-DE
(EUCTR)

18/08/2017

19/04/2017

A study of BIIB092 in participants with Progressive Supranuclear Palsy

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB0092 in Participants with Progressive Supranuclear Palsy

Progressive supranuclear palsy
MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: BIIB092
INN or Proposed INN: BIIB092
Other descriptive name: BIIB092

Biogen Idec Research Limited

NULL

Not Recruiting

Female: yes
Male: yes

459

Phase 2

United States;Greece;Spain;Austria;Russian Federation;Italy;United Kingdom;France;Canada;Australia;Germany;Japan;Korea, Republic of

EUCTR2016-002554-21-GB
(EUCTR)

21/07/2017

10/04/2017

Study of BIIB092 in Participants With Progressive Supranuclear Palsy

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy

Product Code: BIIB092
INN or Proposed INN: BIIB092
Other descriptive name: BIIB092

Biogen Idec Research Limited

NULL

Not Recruiting

Female: yes
Male: yes

459

Phase 2

Canada;Australia;Germany;Japan;Korea, Republic of;United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France

EUCTR2016-002554-21-AT
(EUCTR)

30/06/2017

20/04/2017

Study of BIIB092 in Participants With Progressive Supranuclear Palsy

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy

Product Code: BIIB092
INN or Proposed INN: BIIB092
Other descriptive name: BIIB092

Biogen Idec Research Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

459

Phase 2

United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France;Canada;Australia;Germany;Japan;Korea, Republic of

NCT03068468
(ClinicalTrials.gov)

June 1, 2017

27/2/2017

Study of BIIB092 in Participants With Progressive Supranuclear Palsy

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy

Supranuclear Palsy, Progressive

Drug: BIIB092;Drug: Placebo

Biogen

NULL

Terminated

41 Years

86 Years

All

490

Phase 2

United States;Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02658916
(ClinicalTrials.gov)

February 22, 2016

13/1/2016

Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003

A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered BIIB092 in Patients With Progressive Supranuclear Palsy Who Participated in Study CN002003

Supranuclear Palsy, Progressive

Drug: BIIB092

Biogen

NULL

Terminated

41 Years

86 Years

All

Phase 1

United States

NCT02460094
(ClinicalTrials.gov)

October 2, 2015

20/5/2015

Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear Palsy

Progressive Supranuclear Palsy

Drug: BIIB092;Drug: Placebo

Biogen

NULL

Completed

41 Years

86 Years

All

Phase 1

United States